Forbion European Acquisition priced its initial public offering of 11 million units at $10 per unit. The units list for trading on the Nasdaq as of today under the ticker symbol FRBNU. Each consists of one share and one-third of a redeemable warrant. Once the securities begin separate trading, shares and warrants will be listed under the symbols FRBN and FRBNW, respectively.
Forbion will focus on life sciences companies in Europe.
UBS and Kempen are joint book-running managers. Read more.
